
Opinion|Videos|August 7, 2024
Ideal Goals for Biosimilar Utilization
The panel discusses ideal goals for biosimilar utilization.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the ideal goals for biosimilar utilization?
- Similar to small molecule brands and generics: does the reference product go away and biosimilars have the great majority of utilization?
- Or does reference product stay on the market with pricing concessions?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
4
Value-Based Care Interventions and Management of CKD Progression
5